Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Anemia Treatment Market Report by Disease Type, Therapy Class, Route of Administration, Countries and Company Analysis, 2025-2033" report has been added ...
Could the third time be the charm for an oral HIF-PH inhibitor in the U.S.? GlaxoSmithKline certainly hopes so, with its potential first-in-class medicine now officially up for a decision at the FDA ...
In the race for novel oral drugs to treat anemia of chronic kidney disease, AstraZeneca and FibroGen’s roxadustat held the front-runner position for quite some time. But as that program has now ...
Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe ...
With the NDA target date of October approaching for roxadustat, Fibrogen Inc.'s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia in chronic kidney disease (CKD), watchers of ...
Verywell Health on MSN
Hemolytic anemia causes and treatment
Medically reviewed by Jordana Haber Hazan, MD Hemolytic anemia occurs when red blood cells are destroyed faster than they can ...
August 4th 2020EP. 14: Future Treatment of Anemia in CKD: Impact of HIF Stabilizers August 4th 2020EP. 15: Future Management of Anemia in CKD ...
How Do I Know if I Have Anemia? To diagnose anemia, your doctor will likely ask you about your medical history, perform a physical exam, and order blood tests. You can help by providing detailed ...
TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback